Thermo Fisher ends deal agreement for genetic testing firm Qiagen

Stock Market
© Reuters.  © Reuters.

(Reuters) – Thermo Fisher Scientific (N:) said on Thursday it has terminated its acquisition agreement for German genetic testing company Qiagen (DE:) as the minimum acceptance threshold to its tender offer were not met.

Thermo Fisher’s revised offer had valued Qiagen at 11.3 billion euros ($ 13.38 billion).

Qiagen’s shares fell 1.5% in premarket trading after the announcement.

($ 1 = 0.8445 euros)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Let’s block ads! (Why?)

Stock Market News

Leave a Reply

Your email address will not be published. Required fields are marked *